Stock listing

NASDAQ:OBX Obsidian Therapeutics, Inc. Stock

Follow Obsidian Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:OBX

$12.00 USD -0.21 (-1.7%)

Close on Nov 20, 2026

Past 3 months -23.2% · daily closes, Jul 30, 2026 – Nov 20, 2026, adjusted for splits
Day range
$11.76 – $12.30 USDNov 20, 2026
Volume
336,497 sharesNov 20, 2026
Market cap
$741.3M USDAt the close on Nov 20, 2026 · price × 61.77M shares outstanding
Traded on an average day
$7.86M USDMedian day 378,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OBX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$12.00-0.21-1.7%$12.22$12.30$11.76336,497
$12.21+0.14+1.2%$12.00$13.25$11.73681,209
$12.07-0.29-2.3%$12.26$12.51$11.88282,021
$12.36-0.20-1.6%$12.50$12.71$11.85727,802
$12.56+0.08+0.6%$12.37$13.00$11.80314,041
$12.48-0.40-3.1%$12.99$13.04$12.00328,740
$12.88-0.86-6.3%$13.77$14.00$12.82663,422
$13.74+0.03+0.2%$13.39$14.03$12.74743,997
$13.71-0.16-1.2%$13.34$14.20$12.401,143,732
$13.87+4.27+44.5%$10.41$14.77$9.712,091,400
$9.60-1.39-12.6%$10.98$10.98$9.60778,300
$10.99-2.24-16.9%$13.55$13.75$10.60544,000
$13.23-1.20-8.3%$14.23$14.97$13.01626,800
$14.43-0.36-2.4%$14.62$14.92$13.48526,000
$14.79+0.27+1.9%$14.55$15.52$13.66563,000
$14.52-0.07-0.5%$14.67$15.87$14.30248,200
$14.59+0.34+2.4%$13.38$15.00$13.38412,000
$14.25+0.39+2.8%$13.72$14.31$13.20397,700
$13.86-0.12-0.9%$14.07$14.30$13.16204,800
$13.98+0.04+0.3%$13.83$14.17$13.43279,800
$13.94+0.01+0.1%$14.10$14.50$13.74174,200
$13.93+0.68+5.1%$13.34$14.60$13.34332,800
$13.25+1.31+11.0%$11.97$13.47$11.57410,900
$11.94+0.17+1.4%$11.75$12.00$11.52106,400
$11.77-0.43-3.5%$12.31$12.46$11.62297,700
$12.20-0.02-0.2%$12.31$12.67$12.06240,300
$12.22+0.23+1.9%$12.00$12.67$11.79298,300
$11.99-0.80-6.3%$12.96$13.18$11.86377,300
$12.79-0.21-1.6%$13.13$13.21$12.61420,000
$13.00+0.76+6.2%$12.25$13.95$12.25532,200
$12.24-0.96-7.3%$13.14$13.39$12.07517,100
$13.20-0.02-0.2%$13.02$13.88$12.80359,000
$13.22-0.62-4.5%$13.84$14.42$13.00288,800
$13.84+0.25+1.8%$13.45$14.26$13.09199,200
$13.59+0.27+2.0%$13.07$13.90$13.07229,000
$13.32-0.41-3.0%$13.86$14.68$13.16299,800
$13.73-0.85-5.8%$14.58$14.70$13.11351,600
$14.58+1.21+9.1%$13.28$15.38$12.80378,600
$13.37+0.51+4.0%$12.91$13.73$12.33913,000
$12.86-0.55-4.1%$13.54$13.70$12.16454,500
$13.41-1.85-12.1%$15.27$15.66$13.20426,600
$15.26-1.74-10.2%$17.10$17.10$15.25582,600
$17.00-0.33-1.9%$17.44$17.97$16.711,151,600
$17.33-0.42-2.4%$18.08$18.21$17.141,104,800
$17.75+0.25+1.4%$17.61$18.16$17.363,974,300
$17.50+0.35+2.0%$17.16$18.19$17.16829,600
$17.15+0.15+0.9%$17.29$18.10$16.911,167,000
$17.00-1.10-6.1%$18.17$18.75$17.00472,300
$18.10+0.30+1.7%$18.39$19.00$17.84455,500
$17.80+0.64+3.7%$17.23$18.49$17.17392,800
$17.16-1.52-8.1%$18.65$19.55$17.00454,200
$18.68-0.05-0.3%$18.16$19.97$18.16332,200
$18.73+1.91+11.4%$16.98$19.87$16.98599,400
$16.82-0.27-1.6%$17.26$19.00$16.57140,100
$17.09+0.09+0.5%$16.85$18.06$16.15136,200
$17.00-0.04-0.2%$17.35$18.02$16.25126,300
$17.04-0.47-2.7%$17.18$18.10$16.2779,300
$17.51+1.21+7.4%$16.55$17.99$15.53142,500
$16.30-0.74-4.3%$16.58$18.11$15.85260,500
$17.04-1.36-7.4%$17.80$18.72$16.8065,100
$18.40-0.60-3.2%$18.32$19.20$17.79118,400
$19.00+0.30+1.6%$19.29$19.44$18.50155,712
$18.70-1.20-6.0%$20.39$21.98$17.80133,102
$19.90-0.29-1.4%$20.47$21.33$18.441,449,300
$20.19+0.19+1.0%$20.20$21.03$19.7074,400
Ticker
NASDAQ:OBX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Obsidian Therapeutics, Inc. news

Obsidian Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 4 in all · newest Nov 12, 2026 · oldest 2026
Decks
1 deck · latest August 2026

Valuation

P/E 13.0× against a median of 7.5×: 4th lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$530.4M USD
P/E
13.0×
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Obsidian Therapeutics, Inc. · NASDAQ:OBXUS$741.3MUS$530.4M13.0×n/an/a2.3×n/a0.0×n/a
Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335US$778.7MUS$600.0Mn/an/an/a5.5×n/a0.0×n/a
Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWDUS$778.1MUS$702.9M5.2×1.8×n/an/a37.4%n/a1.16
Syndax Pharmaceuticals, Inc. · NASDAQ:SNDXUS$772.7MUS$695.6Mn/a2.4×n/an/a−72.4%n/a0.64
MeiraGTx Holdings plc · NASDAQ:MGTXUS$766.4MUS$715.6M9.8×1.8×3.7×3.6×19.5%0.6×1.57
ORIC Pharmaceuticals, Inc. · NASDAQ:ORICUS$764.9MUS$503.6Mn/an/an/a2.3×n/a0.0×1.22
Inventiva SA · EURONEXT:IVAUS$760.9MUS$577.3Mn/a117×n/a11.8×n/a1.1×n/a
Rigel Pharmaceuticals, Inc. · NASDAQ:RIGLUS$754.9MUS$663.4M2.5×2.3×8.3×1.7×106.6%0.0×1.02
Monte Rosa Therapeutics, Inc. · NASDAQ:GLUEUS$738.3MUS$196.8Mn/a2.8×n/a1.5×−186.2%0.1×0.92
Aimed Bio Inc. · KRX:0009K0US$726.5MUS$657.3M25.2×13.2×34.0×4.8×57.8%0.0×n/a
Aura Biosciences, Inc. · NASDAQ:AURAUS$715.0MUS$433.9Mn/an/an/a2.5×n/a0.1×1.07
Median of the othersUS$762.9MUS$628.6M7.5×2.4×8.3×3.0×28.4%0.0×1.07

Forecasts

4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
39.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.85 · 1 analyst

Team and board

Officers

OfficerRole
Madan JagasiaChief Executive Officer
Caroline CodeVP Corporate Development and Investor Relations
Nicole HsuVP, Regulatory Affairs

Board

DirectorRole
Maria FardisChair of the Board of Directors
Heidi HagenBoard Member
Madan JagasiaChief Executive Officer
Matthew NorkunasBoard Member
Peter BarrettBoard Member
Rob RossBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close+0.6%
Q2 2026Aug 12, 2026−42.5%
Q1 2026May 11, 2026
Q4 2025Mar 26, 2026
Q3 2025Nov 28, 2025
Q2 2025Aug 29, 2025
Q1 2025May 30, 2025
Quarter to Sep 30, 2024Nov 29, 2024
Quarter to Jun 30, 2024Aug 14, 2024
Quarter to Mar 31, 2024May 13, 2024
All 20 quarters
QuarterResultsShare move
Quarter to Dec 31, 2023Mar 28, 2024
Q3 2023Nov 14, 2023
Q2 2023Aug 14, 2023
Q1 2023May 11, 2023
Q4 2022Mar 8, 2023
Quarter to Sep 30, 2022Nov 9, 2022
Quarter to Jun 30, 2022Aug 9, 2022
Quarter to Mar 31, 2022May 16, 2022
Quarter to Dec 31, 2021Mar 10, 2022
Quarter to Sep 30, 2021Nov 10, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck27 slidesAugust 2026

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development86.1M73.2M
Selling, general and administrative19.6M18.1M
Operating income-105.7M-91.3M
Depreciation and amortization1.48M1.53M
EBITDA-104.2M-89.7M
Income before tax-100.6M-83.1M
Net income-100.6M-83.1M
Earnings per share, basic-1.63-1.35

Balance sheet

LineFY2025FY2024
Cash and equivalents40.4M49.8M
Short-term investments40.1M118.5M
Current assets81.5M172.8M
Total assets88.6M183.7M
Accounts payable12.0K1.82M
Current liabilities15.4M16.1M
Total debt4.28M
Total liabilities354.6M358.1M
Shareholders' equity-266.0M-174.4M
Shares outstanding61.6M61.6M

Cash flow

LineFY2025FY2024FY2022FY2021FY2020
Cash from operations-90.4M-75.0M
Capital spending-73.0K-779.0K000
Free cash flow-90.5M-75.8M
Cash from investing81.0M
Cash from financing20.0K162.5M
Change in cash-9.36M33.6M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4/A · Change in ownership, amendedNov 13, 2026Insider tradeSEC
424B3 · ProspectusNov 12, 2026Offer documentSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 5, 2026Big-stake noticeSEC
All 44 filings
FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveSep 10, 2026Other filingsSEC
S-1 · Registration statementAug 28, 2026Offer documentSEC
8-K/A · Current report, amendedAug 14, 2026Current reportSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 11, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 10, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 10, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 10, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
S-8 · Registration statement for employee plansAug 3, 2026Offer documentSEC
8-K · Current reportAug 3, 2026ResultsSEC
CERT · Exchange's certificate of listingAug 3, 2026Other filingsSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedAug 3, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeAug 3, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 6, 2026Other filingsSEC
424B3 · ProspectusJul 2, 2026Offer documentSEC
S-4/A · Registration statement, amendedJul 2, 2026Offer documentSEC
S-4/A · Registration statement, amendedJun 30, 2026Offer documentSEC
S-4/A · Registration statement, amendedJun 24, 2026Offer documentSEC
S-4/A · Registration statement, amendedJun 2, 2026Offer documentSEC
S-4 · Registration statementApr 22, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Obsidian Therapeutics, Inc.’s releases · as of Nov 9, 2026

Common shares
61,774,046
Fully diluted
61,774,046

Fully diluted

LineSharesAs of
Common shares61,774,046Nov 9, 2026

Share count over time

CountShares
Nov 9, 202661,774,046

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Ra Capital Management, L.P.5.96M9.6%US$81.8MSep 30, 2026
Atlas Venture Life Science Advisors, LLC4.5M7.3%US$61.8MSep 30, 2026
Paradigm Biocapital Advisors LP4.16M6.7%US$57.1MSep 30, 2026
Novo Holdings A/S3.12M5.1%US$42.9MSep 30, 2026
Vanguard2.75M4.5%US$37.8MSep 30, 2026
Trails Edge Capital Partners, LP2.5M4.0%US$34.3MSep 30, 2026
Octagon Capital Advisors LP2.41M3.9%US$33.2MSep 30, 2026
TCG Crossover Management, LLC2.2M3.6%US$30.2MSep 30, 2026
Deep Track Capital, LP2.12M3.4%US$29.1MSep 30, 2026
Citadel1.95M3.2%US$26.7MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Blue Owl Capital Holdings LP1.48M2.4%US$20.4MSep 30, 2026
Spruce Street Capital LP1.25M2.0%US$17.2MSep 30, 2026
Alphabet Inc.1.22M2.0%US$16.8MSep 30, 2026
Nantahala Capital Management, LLC1.2M1.9%US$16.5MSep 30, 2026
Logos Global Management LP1.07M1.7%US$14.6MSep 30, 2026
T. Rowe Price1.06M1.7%US$14.5MSep 30, 2026
Nan Fung Group Holdings Ltd919K1.5%US$12.6MSep 30, 2026
Foresite Capital Management VI LLC916K1.5%US$12.6MSep 30, 2026
Caligan Partners LP886K1.4%US$12.2MSep 30, 2026
Pivotal bioVenture Partners Investment Advisor LLC860K1.4%US$11.8MSep 30, 2026
Samsara Biocapital, LLC837K1.4%US$11.5MSep 30, 2026
Redmile Group, LLC833K1.3%US$11.4MSep 30, 2026
BlackRock776K1.3%US$10.7MSep 30, 2026
Janus Henderson729K1.2%US$10MSep 30, 2026
Eventide Asset Management, LLC625K1.0%US$9.09MSep 30, 2026
Balyasny Asset Management L.P.588K0.95%US$7.8MSep 30, 2026
Longaeva Partners L.P.500K0.81%US$6.63MSep 30, 2026
Geode Capital483K0.78%US$6.64MSep 30, 2026
Revelation Capital Management, LLC428K0.69%US$5.88MSep 30, 2026
Kalehua Capital Management LLC417K0.67%US$5.72MSep 30, 2026
Adage Capital Partners Gp, L.L.C.417K0.67%US$5.72MSep 30, 2026
Woodline Partners LP354K0.57%US$4.86MSep 30, 2026
Ally Bridge Group (NY) LLC302K0.49%US$4.15MSep 30, 2026
Schwab302K0.49%US$4.14MSep 30, 2026
State Street223K0.36%US$3.07MSep 30, 2026
UBS199K0.32%US$2.74MSep 30, 2026
Millennium165K0.27%US$2.27MSep 30, 2026
Ikarian Capital, LLC159K0.26%US$2.18MSep 30, 2026
Boothbay Fund Management, LLC142K0.23%US$1.94MSep 30, 2026
TD141K0.23%US$2.05MSep 30, 2026
Alyeska Investment Group, L.P.125K0.20%US$1.72MSep 30, 2026
Northern Trust103K0.17%US$1.41MSep 30, 2026
Opaleye Management Inc.75,7550.12%US$1.04MSep 30, 2026
Rtw Investments, LP67,7060.11%US$930KSep 30, 2026
Seven Grand Managers, LLC52,0000.08%US$714KSep 30, 2026
Goldman Sachs42,9120.07%US$589KSep 30, 2026
Gts Securities LLC29,1220.05%US$400KSep 30, 2026
Aster Capital Management (DIFC) Ltd26,2360.04%US$360KSep 30, 2026
Seven Fleet Capital Management LP23,0770.04%US$317KSep 30, 2026
BNY11,1630.02%US$153KSep 30, 2026

This page holds 50 of 58 holders. Open Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Peter Barrett
Other companies: Synlogic Inc (Chairman, Partner, Atlas Venture · Since at least Jun 9, 2022); Revvity, Inc. (Partner, Atlas Venture · Since at least May 6, 2022); Larimar Therapeutics, Inc. (Director · May 10, 2022 – May 10, 2022 · Past)
Director · Since at least Aug 3, 2026
Heidi Hagen
Other companies: Vericel Corporation (Director · Since at least Aug 23, 2013); Alaunos Therapeutics, Inc. (Director · Jun 13, 2019 – Sep 2, 2021 · Past)
Director · Since at least Aug 3, 2026
Caroline Code
Other companies: Galera Therapeutics, Inc. (VP Corporate Development & Investor Relations · Since at least Apr 14, 2026)
VP Corporate Development and Investor Relations · Since at least Aug 5, 2026
Maria Fardis
Other companies: CRISPR Therapeutics AG (Director · Since at least Jun 5, 2025)
Director · Since at least Aug 3, 2026
Matthew Norkunas
Other companies: Generation Bio Co (CHIEF FINANCIAL OFFICER · Jan 22, 2021 – Jan 10, 2025 · Past)
Director · Since at least Aug 3, 2026
Robert Ross
Other companies: Xilio Therapeutics, Inc. (Board Member · Since at least Jun 14, 2024)
Director · Since at least Aug 3, 2026
Madan JagasiaChief Executive Officer · Since at least Nov 5, 2026
Nicole HsuVP, Regulatory Affairs · Since at least Nov 5, 2026
Parameswaran HariChief Medical Officer · Since at least Aug 3, 2026

Open People

Log in to ask 6ix AI your own questions about Obsidian Therapeutics, Inc.